Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Sea Limited — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Sea Limited trades at $94.88 (market cap $58.76B). The key difference: Sea Limited is far larger — about 20.5× Dyne Therapeutics Inc. Common Stock's market cap, and Sea Limited is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Sea Limited for 103 Days on average.
| DYN | SE | |
|---|---|---|
Market Cap | $2.86B | $58.76B |
Volume | 3,341,579 | 5,236,560 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $165.70 |
52-Week Low | $14.60 | $78.16 |
Typical Hold Time | 0 Days | 103 Days |
Enterprise Value | $2.18B | $53.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Sea Limited (SE) trades at $95.31, down 0.59% with a bearish technical signal. The company shows strong revenue growth from $22.94B in 2025 to projected $27.7B in 2026, with net income reaching $1.58B. Recent earnings show mixed results with Q4 2025 missing estimates but Q1 and Q2 2026 beating expectations. Analyst consensus remains strongly bullish with 72.7% buy ratings and a $153.67 price target, representing 61% upside potential from current levels.
The investment case hinges on continued e-commerce and fintech growth despite recent stock weakness. Key risks include margin compression concerns and insider selling activity. Positive cash flow generation since 2025 and improving profitability metrics support the bullish analyst outlook, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
